A new approach to treating lupus, based on attacking a wide array of disease-implicated molecular pathways, showed promise in a new study in mice. The target is NF-κB-inducing kinase (NIK), which mediates the function of proteins in the tumor necrosis factor (TNF) family. Members of the family are known to be implicated in…
ImmuPharma has completed a pivotal Phase 3 clinical trial testing Lupuzor (rigerimod) as a lupus treatment and announced an extension study. Findings dealing with the therapy’s effectiveness are expected to be released by the end of April 2018. Lupuzor displayed a robust safety profile after being administered for a year, researchers…
The Lupus Foundation of America recently reviewed the notable achievements and overall advances realized in 2017, finding that significant progress was made both in lupus awareness and in research and advocacy efforts. Highlights for the foundation that helped to advance of lupus awareness and research included the singer Selena Gomez sharing her experience…
Cerebrovascular events are the fourth most frequent neuropsychiatric event in systemic lupus erythematosus (SLE) patients and mostly are due to SLE rather than other causes, a new multi-national study shows. Stroke and transient ischemia were the most common cerebrovascular events in these patients. The research, “Cerebrovascular Events in…
Adding Rituxan (rituximab) to maintenance therapy with immunosuppressants and corticosteroids may help patients control their systemic lupus erythematosus (SLE), a new Japanese study suggests. The study, “Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus,” conducted in a small group of Japanese patients,…
Mixed connective tissue disease (MCTD), a chronic disorder that has overlapping features of two or more systemic rheumatic disorders, is a relatively stable disease that is milder than systemic lupus erythematosus and systemic sclerosis, new research from Norway shows. However, most patients failed to achieve long-term remission. The study, “Disease evolution…
The higher the body mass index, the higher the level of fatigue a lupus patient is likely to experience, Illinois researchers report. They also linked obesity to fatigue levels. Another finding was that reducing fatigue through exercise did not lead to lower levels of adipokines, chemical messengers generated by fat tissue…
Benlysta (belimumab) used in combination with standard of care significantly improved disease activity and reduced prednisone use in patients in Northeast Asia with systemic lupus erythematosus (SLE), a Phase 3 clinical trial found. While the therapy is already approved in the U.S. and Europe for patients with active, autoantibody-positive SLE receiving standard…
A retrospective study shows that 83.9 percent of patients suffering from systemic lupus erythematosus (SLE) and pulmonary arterial hypertension survive at least five years after diagnosis. Also, those with anti-U1-RNP antibodies tend to have better survival rates, the study shows. The research, “Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus:…
The Phase 1b trial testing RA101495 as a treatment for patients with renal impairment diseases, including lupus nephritis, has dosed its first participants, according to Ra Pharmaceuticals. The multi-center trial will determine the pharmacokinetics (how the body metabolizes, distributes, and excretes a drug) of subcutaneous RA101495 in these patients. RA101495…